Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00491686 · ClinicalTrials.gov registry record · Phase 2
AZD6765 for Treatment Resistant Depression
A Phase 2 study of Depression, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 5
- Study locations
NCT00491686: Completed Phase 2 study of Depression, sponsored by AstraZeneca.
NCT00491686 is a Phase 2 study of Depression that has completed, run by AstraZeneca. The registered enrollment target is 34 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00491686, a Phase 2 study of Depression, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to determine whether treatment with AZD6765 will have an antidepressant effect with patients who have treatment resistant depression.
Conditions Studied
Interventions
- DRUG AZD6765
Study Locations (5)
Connecticut
- Research Site - Hartford
- Research Site - New Haven
California
- Research Site - Glendale
Kansas
- Research Site - Wichita
Maryland
- Research Site - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2007-07 |
| Est. Completion | 2007-11 |
| Phase | Phase 2 |
What the finished NCT00491686 record still lists
NCT00491686 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 1 intervention - of which AZD6765 is the first listed.
NCT00491686 lists 5 locations in 4 states (Connecticut, California, Kansas).
Frequently Asked Questions
What is clinical trial NCT00491686 about?
NCT00491686 is a clinical study titled "AZD6765 for Treatment Resistant Depression". The purpose of this study is to determine whether treatment with AZD6765 will have an antidepressant effect with patients who have treatment resistant depression.
What is the current status of trial NCT00491686?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2007-07. Estimated completion is 2007-11.
What conditions does trial NCT00491686 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT00491686?
The interventions under investigation include: AZD6765 (DRUG).
Who is sponsoring clinical trial NCT00491686?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00491686 being conducted?
This trial has 5 study locations across California, Connecticut, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00491686's enrollment target sits among peer trials
34 546th of 679 higher than 132 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
Cannabidiol and Older Adult Cannabis Users
RECRUITING · Phase 2
-
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
RECRUITING · Phase 2
-
Neurobiology of Suicide
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia